MARCHEBIOBANK is a collaborative platform in the field of personalized medicine, focusing on drugs, diagnostics and new therapeutic approaches.
The general objective of the regional platform is to set up and stabilize a synergy-based and effective collaboration between the entrepreneurial and the research worlds within the Marche Region, on such topics as personalized medicine, drugs, diagnostics and new therapeutic approaches — in particular for the management of chronic diseases, high-medical-need oncological diseases and rare diseases.
Activation of a Research Laboratory and Associated Biobank
Institution of a regional non-profit biobank and of a research laboratory, coordinated by Diatech Pharmacogenetics
Research and development projects
3 experimental projects, aimed at setting up innovative, tangible applications within the platform, in the relevant thematic area
- New diagnostic and therapeutic tools for the targeted and personalized treatment of oncological patients coordinated by Diatech Pharmacogenetics
- Platform for the development of new therapeutic instruments, for the personalized treatment of patients with specific needs and rare conditions, coordinated by Angelini
- Development of new pharmaceutical and nutraceutical approaches for the treatment / management of chronic pathologies coordinated by Mivell
Development of a technology transfer platform for the industrialization of new products in the field of personalized medicine and for the treatment and management of chronic diseases, with high-medical-need oncological diseases and rare diseases.
Dissemination and highlighting of th of research and development results from the investment programme, coordinated by the Cluster Marche Foundation.
a 10.3 million euros investment.
public support for 5.4 million euros, namely the 2014-’20 ERDF ROP funds from the Marche Region.
a high-level public-private partnership, including 10 companies, 3 Marche universities and the Cluster Marche Foundation.
a 36-month duration, from 2019 to 2022.
